MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the companies’ co-development and commercialization agreement, the achievement of this milestone triggers a payment of US $ 5 million by MorphoSys to Emergent.
{iframe}http://globenewswire.com/news-release/2015/03/09/713308/10123766/en/MorphoSys-and-Emergent-BioSolutions-Initiate-Phase-1-Clinical-Study-to-Evaluate-the-Novel-Oncology-Immunotherapeutic-MOR209-ES414-for-Prostate-Cancer.html{/iframe}